Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose: To identify a predictive molecular “signature” for sensitivity to retinoic acid in pancreatic cancer. Experimental Design: Fourteen patient-derived, low-passage pancreatic ductal adenocarcinoma (PDAC) lines with varied expression of fatty acid–binding protein 5 (FABP5) and cellular retinoic acid–binding protein 2 (CRABP2) were used to evaluate the response to all-trans retinoic acid (ATRA). Cell proliferation, apoptosis, and migration/invasion assays were used to measure the in vitro response. Tumor growth was monitored in subcutaneous xenografts in athymic nude mice for 4 weeks. Results: Response to ATRA was observed to be dependent upon differential expression of FABP5 versus CRABP2. Thus, elevated FABP5 expression was associated with minimal cytotoxicity and tumor growth inhibition and a paradoxical increase in migration and invasion. Conversely, CRABP2 expression in the absence of FABP5 was associated with significant tumor growth inhibition with ATRA, even in gemcitabine-resistant tumors. The ATRA-resistant phenotype of FABP5highCRABP2null cells could be circumvented by ectopic expression of CRABP2. Alternatively, reexpression of endogenous CRABP2 could be enabled in FABP5highCRABP2null PDAC lines by exposure to decitabine and trichostatin A, thereby relieving epigenetic silencing of the CRABP2 gene promoter. Immunohistochemical staining for FABP5 in archival human tissue microarrays identifies a subset of cases (13 of 63, ∼20%) which are negative for FABP5 expression and might be candidates for ATRA therapy. Conclusions: The widely used agent ATRA deserves a “second look” in PDAC, but needs to be targeted to patient subsets with biopsy-proven FABP5-negative tumors, or be combined with a chromatin-modifying agent to reexpress endogenous CRABP2. Clin Cancer Res; 18(1); 280–9. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1550 · Cited by 1,255 · cited 1×
“A striking example of the pro-carcinogenic effect of RA was observed in the -carotene and Retinol Efficacy Trial (CARET), a lung cancer chemoprevention study that was terminated prematurely due to increased cancer incidence in the treatment cohort (19).”
BackgroundThe promise of retinoids to fight against cancer
Altucci, L., & Gronemeyer, H. (2001) · Nature Reviews Cancer · doi:10.1038/35106036 · Cited by 773 · cited 1×
“The naturally occurring retinoid, all-trans retinoic acid (ATRA) or tretinoin, is approved in the clinic for the treatment of acute promyelocytic leukemia, and is currently being tested in clinical trials in additional tumor types (3).”
Schug, T. T., Berry, D. C., Shaw, N. S., Travis, S. N., & Noy, N. (2007) · Cell · doi:10.1016/j.cell.2007.02.050 · Cited by 680
Tan, N.-S., Shaw, N. S., Vinckenbosch, N., Liu, P., Yasmin, R., Desvergne, B., Wahli, W., & Noy, N. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5114-5127.2002 · Cited by 499
Dong, D., Ruuska, S. E., Levinthal, D. J., & Noy, N. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.23695 · Cited by 362
Shaw, N., Elholm, M., & Noy, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300368200 · Cited by 243 · cited 1×
“Recent seminal studies have elucidated the mechanistic bases for these paradoxical effects of retinoic acid on cell growth and survival (11, 12).”
Schug, T. T., Berry, D. C., Toshkov, I. A., Cheng, L., Nikitin, A. Y., & Noy, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709981105 · Cited by 172
Cited by
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Ideno, N., Yamaguchi, H., Ghosh, B., Gupta, S., Okumura, T., Steffen, D. J., Fisher, C. G., Wood, L. D., Singhi, A. D., Nakamura, M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.006 · Cited by 80
Self-citationParadoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis
Ferri-Borgogno, S., Barui, S., McGee, A. M., Griffiths, T., Singh, P. K., Piett, C. G., Ghosh, B., Bhattacharyya, S., Singhi, A., Pradhan, K., et al. (2020) · Cancers · doi:10.3390/cancers12092695 · Cited by 22
“Anchorage-independent growth assay in soft-agar was performed as described before [53].”
MethodSelf-citation
Metadata
- Authors
- Gupta, S., Pramanik, D., Mukherjee, R., Campbell, N. R., Elumalai, S., de Wilde, R. F., Hong, S.-M., Goggins, M. G., De Jesus-Acosta, A., Laheru, D., & Maitra, A.
- Venue
- Clinical Cancer Research
- Published
- 2012-01-01
- Volume
- 18
- Issue
- 1
- Pages
- 280-289
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2149566991
- Cited by
- 67
- References
- 7
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-2165
- The paper
- Gupta, S., Pramanik, D., Mukherjee, R., Campbell, N. R., Elumalai, S., de Wilde, R. F., Hong, S.-M., Goggins, M. G., De Jesus-Acosta, A., Laheru, D., & Maitra, A. (2012). Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-2165
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.